Comparing the current results to its competitors, Adagene Inc reported Revenue increase in the 4 quarter 2025 by 7332.76 % year on year. The sales growth was above Adagene Inc 's competitors' average revenue growth of 11.47 %, achieved in the same quarter.
Adagene Inc 's Comment on Competition and Industry Peers
The company’s product candidates are regulated by the U.S. Food and Drug Administration (FDA) under the Biologics License Application (BLA) pathway. The Biologics Price Competition and Innovation Act of 2009 (BPCIA) establishes an abbreviated approval process for biosimilars and interchangeable biologics. The company faces competition from biosimilar and other biologic products that may enter the market earlier than expected. Delays in clinical trials could enable competitors to commercialize drugs first, affecting the company’s market efforts. Clinical trials also compete for patient enrollment with trials conducted by other companies in the same therapeutic areas, potentially reducing the pool of available patients. Additionally, cancer patients often receive standard-of-care antibody therapies initially, which can limit enrollment in clinical trials.
February 9, 2024
Adagene, a leading biotechnology company, recently announced the progress and expansion of its clinical collaboration program for their promising drug, ADG126 (also known as muzastotug), in combination with KEYTRUDA (pembrolizumab), targeting patients with metastatic microsatellite-stable (MSS) colorectal cancer (CRC). This collaboration aims to further demonstrate the efficacy of this innovative treatment method.The interim data provided by Adagene indicates that additional MSS CRC patients, who were given a dosage of 10 mg/kg every three weeks (Q3W) in combination with pembrolizumab, have shown significant progress. These findings are expected to be presented at a medical conference in 2024, shedding more ...
89bio Inc operates as a biopharmaceutical company focused on developing and commercializing transformative therapies for liver and cardio-metabolic diseases. The company's business model revolves around identifying and developing potential drug candidates through its unique platform, with the aim of meeting the unmet medical needs of patients. By leveraging its expertise and scientific advancements, 89bio Inc strives to bring innovative treatments to market, improving the lives of individuals suffering from these conditions.
Madrigal Pharmaceuticals Inc's business model is focused on developing and commercializing innovative therapeutic solutions for liver diseases, with a particular emphasis on non-alcoholic steatohepatitis (NASH) and other metabolic diseases. They aim to provide effective treatments to address unmet medical needs and improve patient outcomes in these areas.
Cytodyn Inc is a biotechnology company that focuses on the development and commercialization of innovative treatments for a range of diseases, including cancer and viral infections. The company primarily generates revenue through the licensing and sale of its therapeutics to medical institutions and pharmaceutical companies. Cytodyn's business model revolves around the research and development of novel drugs, conducting clinical trials, and forming strategic partnerships to bring their innovative treatments to market.
Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.
Sources:
Adagene Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Adagene Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
